Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Cash & Current Investments: 2017-2025

Historic Cash & Current Investments for China SXT Pharmaceuticals (SXTC) over the last 9 years, with Mar 2025 value amounting to $18.1 million.

  • China SXT Pharmaceuticals' Cash & Current Investments rose 50.37% to $18.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.4 million, marking a year-over-year increase of 2.64%. This contributed to the annual value of $18.1 million for FY2025, which is 50.11% up from last year.
  • China SXT Pharmaceuticals' Cash & Current Investments amounted to $18.1 million in FY2025, which was up 50.11% from $12.1 million recorded in FY2024.
  • China SXT Pharmaceuticals' Cash & Current Investments' 5-year high stood at $18.1 million during FY2025, with a 5-year trough of $12.1 million in FY2024.
  • Its 3-year average for Cash & Current Investments is $15.9 million, with a median of $17.4 million in 2023.
  • Per our database at Business Quant, China SXT Pharmaceuticals' Cash & Current Investments surged by 83.68% in 2021 and then tumbled by 30.46% in 2024.
  • Over the past 5 years, China SXT Pharmaceuticals' Cash & Current Investments (Yearly) stood at $13.4 million in 2021, then rose by 16.66% to $15.6 million in 2022, then climbed by 11.23% to $17.4 million in 2023, then slumped by 30.46% to $12.1 million in 2024, then spiked by 50.11% to $18.1 million in 2025.